CLAIMS

1. The use of a checkpoint inhibitor, and (ii) non-pathogenic whole cell heat killed *Mycobacterium*, in the manufacture of at least one medicament, (each medicament comprising the checkpoint inhibitor and/or the non-pathogenic heat killed Mycobacterium) for treating, reducing, inhibiting or controlling a neoplasia, tumour or cancer in a subject, wherein each medicament is to be simultaneously, separately or sequentially administered to the subject wherein each medicament results in enhanced therapeutic efficacy relative to administration of the checkpoint inhibitor or *Mycobacterium* alone, wherein the *Mycobacterium* is non-pathogenic whole cell heat killed *Mycobacterium obuense*.

2. The use according to claim 1, wherein said checkpoint inhibitor comprises a blocking agent selected from a cell, protein, peptide, antibody or antigen binding fragment thereof, directed against CTLA-4, PD-1, PD-L1, TIM-3, BTLA, VISTA, LAG-3 and combinations thereof.

3. The use according to claim 1 or 2, wherein said checkpoint inhibitor is a blocking agent, selected from a cell, protein, peptide, antibody or antigen binding fragment thereof, directed against PD-1 or PD-L1.

4. The use according to any of claims 1 to 3, wherein said checkpoint inhibition therapy is to comprise the administration of a sub-therapeutic amount of said blocking agent, selected from a cell, protein, peptide, antibody or antigen binding fragment thereof.

5. The use according to any of claims 1 to 4, wherein said neoplasia, tumour or cancer is selected from prostate cancer, liver cancer, renal cancer, lung cancer, breast cancer, colorectal cancer, breast cancer, pancreatic cancer, brain cancer, hepatocellular cancer, lymphoma, leukaemia, gastric cancer, cervical cancer, ovarian cancer, thyroid cancer, melanoma, carcinoma, head and neck cancer, skin cancer and soft tissue sarcoma.

6. The use according to 5, wherein said neoplasia, tumour or cancer is pancreatic cancer.

7. The use according to any of claims 1 to 6, wherein the neoplasia, tumour or cancer is metastatic.

8. The use according to claim 7, wherein the non-pathogenic heat-killed *Mycobacterium* is a rough variant.

9. The use according to claim 8, wherein the non-pathogenic heat-killed *Mycobacterium* is to be administered via the parenteral, oral, sublingual, nasal or pulmonary route.

10. The use according to claim 9, wherein the parenteral route is selected from subcutaneous, intradermal, subdermal, intraperitonal, or intravenous.

11. The use according to claim 9, wherein the parenteral route does not comprise intratumoural injection.

12. The use according to any of claims 8 to 11, wherein the amount of non-pathogenic heat-killed *Mycobacterium that is to be* administered is from 10^7 to 10^9 cells.

13. The use according to claim 1, wherein enhanced therapeutic efficacy is to be measured by increased overall survival time.

14. The use according to claim 1, wherein enhanced therapeutic efficacy is to be measured by increased progression-free survival.

15. The use according to claim 1, wherein enhanced therapeutic efficacy is to be measured by a decrease or stabilisation of tumour size.

16. The use according to claim 1, wherein enhanced therapeutic efficacy is to be measured by increased quality of life.